Physician profile
Tausif Zar
NPI 1396889358
$6,204.22
in general payments reported to CMS, 2019-2025
28 companies · $2,313 in 2025
The $2,313 reported for 2025 was more than what 90% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $126 · 2021: $256 · 2022: $707 · 2023: $807 · 2024: $1,655 · 2025: $2,313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,140 · Education: $635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,140.26 |
| Education | $635.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $764.81 | 2019-2025 | Rayaldee |
| Astrazeneca Pharmaceuticals LP | $754.42 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $743.98 | 2022-2025 | |
| Amgen INC. | $579.47 | 2022-2025 | Tavneos, Krystexxa |
| Fresenius USA Marketing, INC. | $576.76 | 2019-2025 | Velphoro, Velphoro |
| Mallinckrodt Hospital Products INC. | $556.27 | 2023-2025 | Acthar, Terlivaz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.96 | 2023-2025 | Jardiance |
| Vifor Pharma, INC. | $276.22 | 2019-2024 | Veltassa |
| Novo Nordisk INC | $240.82 | 2024-2025 | Ozempic |
| Ardelyx, INC. | $218.77 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Otsuka America Pharmaceutical, INC. | $177.94 | 2019-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $175.12 | 2022-2025 | Tarpeyo |
| Nxstage Medical, INC. | $162.95 | 2025 | Nxstage System One, Liberty Select Cycler |
| Novartis Pharmaceuticals Corporation | $147.18 | 2019-2025 | |
| Travere Therapeutics, INC. | $118.95 | 2023-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $115.68 | 2020-2023 | Krystexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $45.63 | 2021 | |
| Tactile Systems Technology INC | $43.76 | 2025 | Nimbl, Flexitouch Plus |
| Arbor Pharmaceuticals, INC. | $40.36 | 2019-2021 | |
| Glaxosmithkline, LLC. | $35.68 | 2021-2022 | |
| Outset Medical INC | $31.66 | 2023 | |
| Chiesi USA, INC. | $29.74 | 2024 | Elfabrio |
| Sumitomo Pharma America, INC. | $26.22 | 2025 | Gemtesa |
| Strongbridge US INC. | $20.00 | 2019 | |
| Genzyme Corporation | $16.65 | 2019 | |
| Lilly USA, LLC | $14.40 | 2024 | Jardiance |
| Daiichi Sankyo INC. | $13.82 | 2024 | Injectafer |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tausif Zar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.